These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

257 related items for PubMed ID: 26871297

  • 1. Extended-release guanfacine hydrochloride in 6-17-year olds with ADHD: a randomised-withdrawal maintenance of efficacy study.
    Newcorn JH, Harpin V, Huss M, Lyne A, Sikirica V, Johnson M, Ramos-Quiroga JA, van Stralen J, Dutray B, Sreckovic S, Bloomfield R, Robertson B.
    J Child Psychol Psychiatry; 2016 Jun; 57(6):717-28. PubMed ID: 26871297
    [Abstract] [Full Text] [Related]

  • 2. A Randomized, Placebo-Controlled Trial of Guanfacine Extended Release in Adolescents With Attention-Deficit/Hyperactivity Disorder.
    Wilens TE, Robertson B, Sikirica V, Harper L, Young JL, Bloomfield R, Lyne A, Rynkowski G, Cutler AJ.
    J Am Acad Child Adolesc Psychiatry; 2015 Nov; 54(11):916-25.e2. PubMed ID: 26506582
    [Abstract] [Full Text] [Related]

  • 3. Efficacy and safety of extended-release guanfacine hydrochloride in children and adolescents with attention-deficit/hyperactivity disorder: a randomized, controlled, phase III trial.
    Hervas A, Huss M, Johnson M, McNicholas F, van Stralen J, Sreckovic S, Lyne A, Bloomfield R, Sikirica V, Robertson B.
    Eur Neuropsychopharmacol; 2014 Dec; 24(12):1861-72. PubMed ID: 25453486
    [Abstract] [Full Text] [Related]

  • 4. Randomized, double-blind trial of guanfacine extended release in children with attention-deficit/hyperactivity disorder: morning or evening administration.
    Newcorn JH, Stein MA, Childress AC, Youcha S, White C, Enright G, Rubin J.
    J Am Acad Child Adolesc Psychiatry; 2013 Sep; 52(9):921-30. PubMed ID: 23972694
    [Abstract] [Full Text] [Related]

  • 5. Does Guanfacine Extended Release Impact Functional Impairment in Children with Attention-Deficit/Hyperactivity Disorder? Results from a Randomized Controlled Trial.
    Stein MA, Sikirica V, Weiss MD, Robertson B, Lyne A, Newcorn JH.
    CNS Drugs; 2015 Nov; 29(11):953-62. PubMed ID: 26547425
    [Abstract] [Full Text] [Related]

  • 6. Response/remission with guanfacine extended-release and psychostimulants in children and adolescents with attention-deficit/hyperactivity disorder.
    Cutler AJ, Brams M, Bukstein O, Mattingly G, McBurnett K, White C, Rubin J.
    J Am Acad Child Adolesc Psychiatry; 2014 Oct; 53(10):1092-101. PubMed ID: 25245353
    [Abstract] [Full Text] [Related]

  • 7. Efficacy and Safety of Guanfacine Extended-Release in the Treatment of Attention-Deficit/Hyperactivity Disorder in Adults: Results of a Randomized, Double-Blind, Placebo-Controlled Study.
    Iwanami A, Saito K, Fujiwara M, Okutsu D, Ichikawa H.
    J Clin Psychiatry; 2020 Apr 14; 81(3):. PubMed ID: 32297719
    [Abstract] [Full Text] [Related]

  • 8. Efficacy and safety of guanfacine extended-release in Japanese adults with attention-deficit/hyperactivity disorder: Exploratory post hoc subgroup analyses of a randomized, double-blind, placebo-controlled study.
    Naya N, Sakai C, Okutsu D, Kiguchi R, Fujiwara M, Tsuji T, Iwanami A.
    Neuropsychopharmacol Rep; 2021 Mar 14; 41(1):26-39. PubMed ID: 33305542
    [Abstract] [Full Text] [Related]

  • 9. A controlled trial of extended-release guanfacine and psychostimulants for attention-deficit/hyperactivity disorder.
    Wilens TE, Bukstein O, Brams M, Cutler AJ, Childress A, Rugino T, Lyne A, Grannis K, Youcha S.
    J Am Acad Child Adolesc Psychiatry; 2012 Jan 14; 51(1):74-85.e2. PubMed ID: 22176941
    [Abstract] [Full Text] [Related]

  • 10. Guanfacine extended release: a novel treatment for attention-deficit/hyperactivity disorder in children and adolescents.
    Faraone SV, McBurnett K, Sallee FR, Steeber J, López FA.
    Clin Ther; 2013 Nov 14; 35(11):1778-93. PubMed ID: 24139092
    [Abstract] [Full Text] [Related]

  • 11. Efficacy of guanfacine extended release in the treatment of combined and inattentive only subtypes of attention-deficit/hyperactivity disorder.
    Sallee FR, Kollins SH, Wigal TL.
    J Child Adolesc Psychopharmacol; 2012 Jun 14; 22(3):206-14. PubMed ID: 22612526
    [Abstract] [Full Text] [Related]

  • 12. Guanfacine extended release as adjunctive therapy to psychostimulants in children and adolescents with attention-deficit/hyperactivity disorder.
    Childress AC.
    Adv Ther; 2012 May 14; 29(5):385-400. PubMed ID: 22610723
    [Abstract] [Full Text] [Related]

  • 13. Combined Stimulant and Guanfacine Administration in Attention-Deficit/Hyperactivity Disorder: A Controlled, Comparative Study.
    McCracken JT, McGough JJ, Loo SK, Levitt J, Del'Homme M, Cowen J, Sturm A, Whelan F, Hellemann G, Sugar C, Bilder RM.
    J Am Acad Child Adolesc Psychiatry; 2016 Aug 14; 55(8):657-666.e1. PubMed ID: 27453079
    [Abstract] [Full Text] [Related]

  • 14. Psychomotor functioning and alertness with guanfacine extended release in subjects with attention-deficit/hyperactivity disorder.
    Kollins SH, López FA, Vince BD, Turnbow JM, Farrand K, Lyne A, Wigal SB, Roth T.
    J Child Adolesc Psychopharmacol; 2011 Apr 14; 21(2):111-20. PubMed ID: 21476931
    [Abstract] [Full Text] [Related]

  • 15. Cost effectiveness of guanfacine extended-release versus atomoxetine for the treatment of attention-deficit/hyperactivity disorder: application of a matching-adjusted indirect comparison.
    Erder MH, Xie J, Signorovitch JE, Chen KS, Hodgkins P, Lu M, Wu EQ, Sikirica V.
    Appl Health Econ Health Policy; 2012 Nov 01; 10(6):381-95. PubMed ID: 23113551
    [Abstract] [Full Text] [Related]

  • 16. Guanfacine extended release adjunctive to a psychostimulant in the treatment of comorbid oppositional symptoms in children and adolescents with attention-deficit/hyperactivity disorder.
    Findling RL, McBurnett K, White C, Youcha S.
    J Child Adolesc Psychopharmacol; 2014 Jun 01; 24(5):245-52. PubMed ID: 24945085
    [Abstract] [Full Text] [Related]

  • 17. Guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder: a placebo-controlled trial.
    Sallee FR, McGough J, Wigal T, Donahue J, Lyne A, Biederman J, SPD503 STUDY GROUP.
    J Am Acad Child Adolesc Psychiatry; 2009 Feb 01; 48(2):155-65. PubMed ID: 19106767
    [Abstract] [Full Text] [Related]

  • 18. Evaluating Guanfacine Hydrochloride in the Treatment of Attention Deficit Hyperactivity Disorder (ADHD) in Adult Patients: Design, Development and Place in Therapy.
    Ota T, Yamamuro K, Okazaki K, Kishimoto T.
    Drug Des Devel Ther; 2021 Feb 01; 15():1965-1969. PubMed ID: 34007156
    [Abstract] [Full Text] [Related]

  • 19. Modeling and simulation of the exposure-response and dropout pattern of guanfacine extended-release in pediatric patients with ADHD.
    Knebel W, Rogers J, Polhamus D, Ermer J, Gastonguay MR.
    J Pharmacokinet Pharmacodyn; 2015 Feb 01; 42(1):45-65. PubMed ID: 25373474
    [Abstract] [Full Text] [Related]

  • 20. Treatment Patterns, Health Care Resource Utilization, and Health Care Cost Associated with Atypical Antipsychotics or Guanfacine Extended Release in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder in Quebec, Canada.
    Lachaine J, Ben Amor L, Pringsheim T, Burns J, van Stralen J.
    J Child Adolesc Psychopharmacol; 2019 Dec 01; 29(10):730-739. PubMed ID: 31433205
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.